Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 363-367

  Nelius, Thomas ^b   Klatte, Tobias ^c   De Riese, Werner ^a   Haynes, Allan ^a   Filleur, Stephanie ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Cyclophosphamide; Docetaxel; Hormone refractory prostate cancer; Metronomic chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ANEMIA; ANGIOGENESIS; ARTICLE; ASTHENIA; BONE PAIN; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GRANULOCYTOPENIA; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; KAPLAN MEIER METHOD; LOW DRUG DOSE; MALAISE; METASTASIS; METRONOMIC THERAPY; NAUSEA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 77956363740     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9218-8     Document Type: Article

References (26)

1. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098-109. doi:10.1002/1097-0142(19930201)71:3?\1098<:AID-CNCR282 0711432>3.0.CO;2-G.
2. Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005;23:3343-51. doi:10.1200/JCO.2005.12.187.
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20. doi:10.1056/NEJMoa041318. (Pubitemid 39315318)
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12. doi:10.1056/NEJ Moa040720.
5. Nelius T, Klatte T, Yap R, et al. A randomized study of docetaxel and dexamethasone with - or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU Int. 2006;98:580-5. doi:10.1111/j.1464- 410X.2006.06324.x. (Pubitemid 44185880)
6. Nelius T, Reiher F, Lindenmeir T, et al. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Onkologie. 2005;28:573-8. doi:10.1159/000088297. (Pubitemid 41513143)
7. Chowdhury S, Burbridge S, Harper PG. Chemotherapy for the treatment of hormone-refractory prostate cancer. Int J Clin Pract. 2007;61:2064-70. doi:10.1111/j.1742-1241.2007.01551.x. (Pubitemid 350077400)
8. Nicolini A, Mancini P, Ferrari P, et al. Oral -dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother. 2004;58:447-50.
9. Lord R, Nair S, Schache A, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol. 2007;177:2136-40. doi:10.1016/j.juro.2007. 01.143. discussion 2140.
10. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(?)25 ? T regulatory cell function implicated in enhanced immune response by -dose cyclophosphamide. Blood. 2005;105: 2862-8. doi:10.1182/blood-2004-06-2410. (Pubitemid 40446280)
11. Damber JE, Vallbo C, Albertsson P, et al. The anti-tumour effect of -dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol. 2006;58:354-60. doi:10.1007/s00280-005-0163-8. (Pubitemid 43800739)
12. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-7. doi:10.1172/ JCI9872.
13. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60
14. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002;62:2731-5.
15. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 2005;65:7045-51. doi:10.1158/0008-5472.CAN-05-0765. (Pubitemid 41161230)
16. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-7.
17. Beekman KW, Fleming MT, Scher HI, et al. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer. 2005;4:86-90.
18. Hellerstedt B, Pienta KJ, Redman BG, et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen- independent prostate carcinoma. Cancer. 2003;98:1603-10. doi:10.1002/cncr.11686. (Pubitemid 37238615)
19. Brandes LJ, Bracken SP, Ramsey EW. N, N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine in combination with cyclophosphamide: an active, -toxicity regimen for metastatic hormonally unresponsive prostate cancer. J Clin Oncol. 1995;13:1398-403.
20. Muss HB, Howard V, Richards F 2nd, et al. Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. Cancer. 1981; 47:1949-53. doi:10.1002/1097-0142(19810415) 47:8\1949::AIDCNCR2820470806[3.0.CO;2-3.
21. Bracarda S, Tonato M, Rosi P, et al. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Cancer. 2000;88:1438-44. doi:10.1002/(SICI)1097- 0142(20000315)88:6\1438::AID-CNCR 23[3.0.CO;2-O.
22. Glode LM, Barqawi A, Crighton F, et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003;98:1643-8. doi:10.1002/cncr.11713. (Pubitemid 37238620)
23. Nishimura K, Nonomura N, Ono Y, et al. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone- refractory prostate cancer. Oncology. 2001;60:49-54. doi: 10.1159/000055296. (Pubitemid 32041431)
24. Albertsson P, Lennernas B, Norrby K. Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. Apmis. 2003;111:995-1003. doi:10.1111/j.1600-0463.2003.apm1111102.x. (Pubitemid 37521892)
25. Nicholson B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem. 2004;91:125-50. doi:10.1002/ jcb.10772.
26. Hamano Y, Sugimoto H, Soubasakos MA, et al. Thrombospondin- 1 associated with tumor microenvironment contributes to dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004;64:1570-4. doi: 10.1158/0008-5472.CAN-03-3126. (Pubitemid 38428672)